A Single-Arm, Open-label, Phase II Study Evaluating the Efficacy and Safety of Abemaciclib in Patients With Recurrent Oligodendroglioma
University of Pennsylvania
ClinicalTrials.gov Identifier: NCT03969706
Hospital of the University of Pennsylvania [Photo: Penn Medicine]Investigators at the University of Pennsylvania have started a Phase II, single-arm, open-label study looking how well abemaciclib (VerzenioTM, Lilly) works in patients with recurrent oligodendroglioma.
See additional details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to avery@williamaveryhudson.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center / Bayer
ClinicalTrials.gov Identifier: NCT03877055
Memorial Sloan Kettering Cancer Center [Photo: National Cancer Institute]Investigators at Memorial Sloan Kettering Cancer Center have opened a Phase I/II clinical trial to test the safety and any positive and negative side effects of combining two study drugs, copanlisib (ALIQOPATM, Bayer) and ibrutinib (IMBRUVICA®, Pharmacyclics, Janssen Biotech), in the treatment of mantle cell lymphoma.
See additional details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to avery@williamaveryhudson.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center / Merck Sharp & Dohme Corp. / National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03873818
The University of Texas MD Anderson Cancer Center [Photo: National Cancer Institute]Investigators at M. D. Anderson Cancer Center have opened a Phase II clinical trial to study the side effects and how well low-dose ipilimumab (YERVOY®, Bristol‑Myers Squibb) works in combination with pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme) in treating patients with melanoma that has spread to the brain.
See additional details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to avery@williamaveryhudson.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
Albert Einstein College of Medicine / Pancreatic Cancer Action Network (PCAN)
ClinicalTrials.gov Identifier: NCT03848182
Resnick Campus, Albert Einstein College of Medicine [Photo: Albert Einstein College of Medicine]Investigators at Albert Einstein College of Medicine, in collaboration with the Pancreatic Cancer Action Network (PCAN), have opened a Phase II clinical trial of gemcitabine with tetanus toxoid vaccine booster for patients with pancreatic cancer. Patients diagnosed with pancreatic ductal carcinoma will be treated with gemcitabine as standard of care and boosted once with the human childhood vaccine to tetanus toxoid.
From the study summary:
“The investigator is developing an immune therapy against pancreatic cancer. Immune cells, known as ‘T cells with tumor killing capacity’, are involved in this immune therapy. In mice with pancreatic cance there is evidence that one tetanus toxoid (TT) vaccination (that patients receive from childhood) combined with Gemcitabine activates these killer T cells. (Gemcitabine improves T cell responses.) These killer T cells are able to destroy tumor cells uploaded with TT protein (such studies are planned in future clinical trials). The goal of this study is to test whether one TT vaccination combined with Gemcitabine treatment activates the same T cells in pancreatic cancer patients.”
See additional details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to avery@williamaveryhudson.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Columbia University / Pfizer
ClinicalTrials.gov Identifier: NCT03839498
Axitinib PubChem CID: 6450551
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center [Photo: National Cancer Institute]Investigators at Columbia University Medical Center have opened a Phase I clinical trial to determine the activity of axitinib (INLYTA®, Pfizer) as a single agent in tumor and hormonal responses in malignant pheochromocytoma/paraganglioma.
See complete details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to avery@williamaveryhudson.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.
Window of Opportunity Trial of Abemaciclib for Bladder Cancer
Weill Medical College of Cornell University / Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT03837821
Abemaciclib PubChem CID: 46220502
Weill Medical College of Cornell University – New York, NY [Photo: Cornell010, Wikimedia Commons]Investigators at Weill Medical College of Cornell University have opened a Phase I “Window of Opportunity” clinical trial of neoadjuvant abemaciclib (Verzenio®, Eli Lilly and Company) followed by radical cystectomy in patients with platinum-ineligible urothelial carcinoma (bladder cancer) to evaluate CDK4/6-dependent phosphorylation of pocket proteins and clonal evolution dynamics.
See complete details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to avery@williamaveryhudson.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Children’s Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier: NCT03825289
Venetoclax PubChem CID: 11707110
Vyxeos PubChem CID: 11707110
Children’s Hospital Medical Center, Cincinnati [Photo: Cincinnati Children’s Hospital Medical Center]Investigators at Children’s Hospital Medical Center, Cincinnati, have opened a Phase I clinical trial to study the safety and tolerability of combining venetoclax (VENCLEXTA®, AbbVie) with VYXEOS® (CPX-351, daunorubicin and cytarabine, Jazz Pharmaceuticals) in pediatric and young adult patients with acute leukemia that has come back or has not responded to treatment.
See complete details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to avery@williamaveryhudson.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.
Trametinib and Hydroxychloroquine in Treating Patients with Pancreatic Cancer (THREAD)
University of Utah / Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03825289
Trametinib PubChem CID: 11707110
Huntsman Cancer Institute, University of Utah [Photo: National Cancer Institute]Investigators at the Huntsman Cancer Institute at the University of Utah are conducting a Phase I clinical trial to study the side effects and best dose of hydroxychloroquine when given together with trametinib (MEKINIST®, Novartis) in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes, or other places in the body and cannot be removed by surgery.
See complete details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to avery@williamaveryhudson.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.
Oncology Publications & Clinical Research, Updated in Real Time
I invite you to bookmark a new website I’ve launched at OncologyWatch.com. OncologyWatch delivers updated listings of journal publications and clinical trials, updated in real time as they are published.
Two open-access references are essential to OncologyWatch: PubMed, the archive of biomedical and life sciences journal literature maintained by the US National Institutes of Health’s National Library of Medicine; and ClinicalTrials.gov, the registry and results database of publicly and privately supported clinical studies of human participants conducted around the world, also maintained by NIH.
Photo: Osteosarcoma Cells (Michael Blank, Ying Zhang, NCI Center for Cancer Research)
Browse or search OncologyWatch to find your target cancer (the nomenclature mirrors that of the US National Cancer Institute’s index of cancer types). One click executes a customized search for relevant journal articles and clinical trials. Once you land on the NIH sites, you’ll have the option to further customize your searches. Filter for articles with free full text, for example, or for clinical trials in a specific geographic location.
Why I Built OncologyWatch
OncologyWatch is one of two websites that I maintain to provide information relevant to health care. My other site, A Knowledge Machine, provides a broad range of information relevant to health, art, and social progress.
The epistemological method for my websites derives from “As We May Think,” a 1945 Atlantic Monthly essay by Vannevar Bush, President Roosevelt’s science adviser during World War II. Bush’s vision led to the development of the hyperlink and the World Wide Web.
Over the past three decades, I’ve had the good fortune to work with many smart and generous colleagues in the not-for-profit and for-profit sectors who have taught me a great deal and given me the opportunity to help them weave the stuff of the future.
OncologyWatch and A Knowledge Machine reproduce and support the ongoing diligence that now informs my work as a public relations consultant for clients in health, art, and social progress organizations.
To make full use of my work, consider also following my blog posts and Twitter feed as I build my next-generation integrated web platform in support of activists for peace, sound environmental stewardship, humane economic policy, and promotion of human health and creativity.
